Q32 Bio
QTTB
Q32 Bio (QTTB) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.78
- EPS estimate
- −$0.98
- EPS surprise
- +20.27%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 6, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 6, 2025 | −$0.98 | −$0.78 | +20.27% | $0.00 | SEC |
| Q1 2025 | May 8, 2025 | −$1.23 | −$0.90 | +26.83% | $0.00 | SEC |
| Q4 2024 | Mar 11, 2025 | −$1.53 | −$1.16 | +24.20% | $0.00 | SEC |
| Q3 2024 | Nov 7, 2024 | −$1.38 | −$1.46 | −5.87% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$1.00 | −$1.42 | −42.47% | $0.00 | SEC |
| Q1 2024 | May 9, 2024 | −$1.42 | −$6.33 | −347.35% | $0.00 | SEC |
| Q4 2023 | Mar 13, 2024 | −$5.40 | −$3.31 | +38.70% | −$14.7M | SEC |
| Q3 2023 | Nov 14, 2023 | −$7.56 | −$10.26 | −35.71% | $0.00 | SEC |
| Q2 2023 | Aug 14, 2023 | −$8.51 | −$10.98 | −29.10% | $354,000.00 | SEC |
| Q1 2023 | May 11, 2023 | −$9.54 | −$9.00 | +5.66% | $802,000.00 | SEC |
| Q4 2022 | Mar 9, 2023 | −$8.86 | −$10.80 | −21.89% | $802,000.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$8.21 | −$10.62 | −29.28% | $802,000.00 | — |
| Q2 2022 | Aug 15, 2022 | −$9.68 | −$9.18 | +5.13% | $802,000.00 | — |
| Q3 2021 | Nov 15, 2021 | −$10.57 | −$9.72 | +8.01% | $1.7M | — |
| Q2 2021 | Aug 12, 2021 | −$10.35 | −$9.72 | +6.09% | $2.2M | — |
| Q1 2021 | May 6, 2021 | −$11.05 | −$0.36 | +96.74% | $29.3M | — |
| Q4 2020 | Mar 11, 2021 | −$11.86 | −$11.16 | +5.88% | $980,000.00 | — |
| Q3 2020 | Nov 9, 2020 | −$14.56 | −$11.16 | +23.34% | $567,000.00 | SEC |
| Q2 2020 | Aug 10, 2020 | −$13.32 | −$14.04 | −5.41% | $567,000.00 | — |
| Q1 2020 | May 7, 2020 | −$12.42 | −$14.04 | −13.04% | $588,000.00 | — |
Quarterly revenue
Frequently asked questions
When did Q32 Bio (QTTB) last report earnings?
Q32 Bio last reported on Aug 6, 2025, covering fiscal Q2 2025.
Did QTTB beat earnings estimates?
Yes. Q32 Bio reported EPS of −$0.78 for Q2 2025 against a −$0.98 estimate — a 20.27% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.